1. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
- Author
-
Hyman B. Muss, Paul E. Goss, Catherine A. Schnabel, Elizabeth Zarrella, Jackie Szymonifka, Dennis C. Sgroi, Yi Zhang, Erin Carney, Peggy L. Porter, Shemeica Binns, Dianne M. Finkelstein, Katherine I. Pritchard, David L. Rimm, James N. Ingle, Atul K. Bhan, Mark G. Erlander, Lois E. Shepherd, Dongsheng Tu, and Lauren Steffel
- Subjects
Oncology ,Cancer Research ,Receptor, ErbB-2 ,0302 clinical medicine ,Prospective Studies ,0303 health sciences ,Receptors, Interleukin-17 ,Aromatase Inhibitors ,Reverse Transcriptase Polymerase Chain Reaction ,Incidence ,Letrozole ,Middle Aged ,Prognosis ,Primary tumor ,3. Good health ,Receptors, Estrogen ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,Receptors, Progesterone ,medicine.drug ,Adult ,medicine.medical_specialty ,Antineoplastic Agents ,Breast Neoplasms ,Disease-Free Survival ,Article ,03 medical and health sciences ,Breast cancer ,Predictive Value of Tests ,Internal medicine ,Nitriles ,Biomarkers, Tumor ,medicine ,Adjuvant therapy ,Humans ,Aged ,Neoplasm Staging ,Retrospective Studies ,030304 developmental biology ,Homeodomain Proteins ,Gynecology ,business.industry ,Case-control study ,Cancer ,Receptors, Interleukin ,Triazoles ,medicine.disease ,Clinical trial ,Logistic Models ,Case-Control Studies ,Multivariate Analysis ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,Tamoxifen - Abstract
Patients with hormone receptor–positive early breast cancer have a continuous yearly rate of recurrence extending out to 15 years after having received adjuvant endocrine therapy with tamoxifen for 5 years (1). More than half of the recurrences and about two-thirds of breast cancer deaths in this group will occur beyond 5 years from diagnosis (ie, late recurrences and death) (1). The National Cancer Institute of Canada (NCIC) Clinical Trials Group MA.17 trial was a randomized, placebo-controlled trial demonstrating that extended endocrine therapy with letrozole improves disease-free survival (DFS) (2), distant DFS (DDFS), and overall survival (OS) in disease-free postmenopausal patients with hormonal receptor–positive breast cancer after 5 years of tamoxifen (3). Although extended antihormonal therapy has become standard practice and is endorsed by international clinical practice guidelines (4,5), understanding which patients will actually benefit from longer treatment is paramount to individualized therapy. The status of primary tumor estrogen receptor (ER) and progesterone receptor (PR) expression has been suggested, but not confirmed, as a way to identify patients who have increased benefit from extended letrozole (5). Patients with ER+ and PR+ tumors have been shown to have improved DFS (P = .02) when compared with patients with ER+ and PR− tumors (6). Currently, however, there are no guideline-accepted biomarkers to stratify hormonal receptor–positive patients for prediction of benefit beyond the 5 years of adjuvant endocrine therapy. In addition, standard clinico-pathological factors and clinically available genomic signatures, including the 21-gene (Recurrence Score) assay (7) and the 70-gene assay (8), have greatest prognostic performance for recurrence risk within the first 5 years of adjuvant therapy. Identification of additional biomarkers to further stratify hormone receptor–positive tumors to predict those at risk of late recurrence and those who may or may not benefit from extended endocrine therapy would be of substantial clinical utility (9). We have previously demonstrated that the two-gene expression ratio, HOXB13/IL17BR (H/I), is a prognostic biomarker in both untreated and tamoxifen-treated early-stage ER+ breast cancer patients (10–13). However, potential assessment of H/I as a predictive biomarker for endocrine therapy has been limited by the analysis of retrospective/observational cohorts or by the use of single treatment arm cohorts from randomized trials (11–13). Herein, we have conducted a prospective–retrospective (14), nested case-control study in a subset of patients from NCIC Clinical Trials Group MA.17 trial to evaluate the performance of H/I for 1) prognostication of late disease recurrence and 2) prediction of treatment benefit from extended adjuvant letrozole therapy in patients with hormone receptor–positive early breast cancer.
- Published
- 2013
- Full Text
- View/download PDF